Research has demonstrated that in tumor cells, Lu/BCAM competes with integrin α3β1 to bind to LM-511, resulting in weakened intercellular adhesion and an enhanced tumor cell migration ability [14]. This evidence concerns the gene BCAM and neoplasm.